Ahmed Sultan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ahmed Sultan has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed Abdel Wahab
Gastrointestinal Surgery Center, Mansoura University, Mansoura, Egypt
17 shared publications F Ezzat
14 shared publications- Omar Fathy
Gastroenterology Center, Mansoura University, Egypt
10 shared publications - Gamal El Ebidy
Gastroenterology Surgical Center, Mansoura University, Mansoura, Egypt
7 shared publications - Tarek Salah
Liver Transplantation Unit and Gastroenterology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt
6 shared publications - Amgad Fouad
Gastrointestinal Surgery Center, Department of Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt
5 shared publications
Latest Publications
- Open Access
- 27 April 2023
- Published by European Publishing in Population Medicine
- Vol. 5 (Supplement)
Association between risk for Prediabetes and Type 2 Diabetes Mellitus prevention practices among King Faisal University faculty members and administrative staff
Background: Diabetes continues to rise globally. The disease brings patients, their families, and healthcare systems significant financial losses, including decreased productivity and burden economies. In 2021, diabetes affected approximately 537 million adults between the ages 20-79 years...
- 27 April 2023
- Published by European Publishing in Population Medicine
- Vol. 5 (Supplement)
Open AccessAssociation between risk for Prediabetes and Type 2 Diabetes Mellitus prevention practices among King Faisal University faculty members and administrative staff
Background: Diabetes continues to rise globally. The disease brings patients, their families, and healthcare systems significant financial losses, including decreased productivity and burden economies. In 2021, diabetes affected approximately 537 million adults between the ages 20-79 years...
- Open Access
- 1 July 2022
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 88 (1) , 2491-2495
Right Mini-Thoracotomy Aortic Valve Replacement Versus Full Sternotomy Approach
Background: For a long time, full median sternotomy was the standard approach for heart surgery. With the advancement of the new technology there is a trend for minimal invasion in all types of surgeries including heart surgery aiming to avoiding and minimizing surgical trauma and morbidity. Objective: The aim of the current work was to compare the outcome of right mini-thoracotomy aortic valve replacement versus full sternotomy. Patients and Methods: A retrospective study that was done in multicentre in in Cairo University and Beni-Suef University. Between June 2015 to October 2021, 219 patients had aortic valve replacement for aortic valve disease of them 124 had the surgery through full sternotomy and 95 patients had it through right mini thoracotomy. We collected their clinical data and compared their inpatient course and outcome. Results: Right mini-thoracotomy was associated with more aortic cross clamp, total bypass and total surgery time, but less mechanical ventilation, blood loss, blood transfusion, ICU stay, re-exploration for bleeding than the full sternotomy group. Also, it was associated with less wound complications with no significant difference in mortalities in both groups. In addition, it had shorter hospital stay that was 6.9 ± 0.8 days (mean ±SD) in comparison to 8.2 ± 1.1 days (mean ±SD) in the full sternotomy group with a p value of 0.02. Also, right mini-thoracotomy showed more patient satisfaction and shorter wound than the full sternotomy group.Conclusion: It could be concluded that right Mini-thoracotomy aortic valve replacement is safe alternative to full sternotomy with shorter MV, ICU and inpatient stay, less wound infection, smaller wound and more patient satisfaction but with longer cross clamp, bypass and surgery time.
- 1 July 2022
- Published by Egyptian Knowledge Bank in The Egyptian Journal of Hospital Medicine
- Vol. 88 (1) , 2491-2495
Open AccessRight Mini-Thoracotomy Aortic Valve Replacement Versus Full Sternotomy Approach
Background: For a long time, full median sternotomy was the standard approach for heart surgery. With the advancement of the new technology there is a trend for minimal invasion in all types of surgeries including heart surgery aiming to avoiding and minimizing surgical trauma and morbidity. Objective: The aim of the current work was to compare the outcome of right mini-thoracotomy aortic valve replacement versus full sternotomy. Patients and Methods: A retrospective study that was done in multicentre in in Cairo University and Beni-Suef University. Between June 2015 to October 2021, 219 patients had aortic valve replacement for aortic valve disease of them 124 had the surgery through full sternotomy and 95 patients had it through right mini thoracotomy. We collected their clinical data and compared their inpatient course and outcome. Results: Right mini-thoracotomy was associated with more aortic cross clamp, total bypass and total surgery time, but less mechanical ventilation, blood loss, blood transfusion, ICU stay, re-exploration for bleeding than the full sternotomy group. Also, it was associated with less wound complications with no significant difference in mortalities in both groups. In addition, it had shorter hospital stay that was 6.9 ± 0.8 days (mean ±SD) in comparison to 8.2 ± 1.1 days (mean ±SD) in the full sternotomy group with a p value of 0.02. Also, right mini-thoracotomy showed more patient satisfaction and shorter wound than the full sternotomy group.Conclusion: It could be concluded that right Mini-thoracotomy aortic valve replacement is safe alternative to full sternotomy with shorter MV, ICU and inpatient stay, less wound infection, smaller wound and more patient satisfaction but with longer cross clamp, bypass and surgery time.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 115
Abstract 115: Combined treatment of letrozole or olaparib with aspirin inhibits cell proliferation and induces apoptosis through upregulation of wild p53 and modulation of aurora kinases in human breast cancer cell lines
Although, there are several breakthroughs in the treatment of breast cancer on the past few decades, high incidence of relapse and progression after conventional therapies is deeply concerning, indicating a great need for developing new therapeutics for breast cancer. In the present study, the anti-cancer effects of combinational therapy of Letrozole (Aromatase inhibitor) or Olaparib (PARP inhibitor) with Aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), were examined on well differentiated ER-positive and poorly differentiated triple negative breast cancer cell lines, T-47D and MDA-MB-231, respectively. In addition, the effect of combined treatment was also examined by detecting cell survival, cell cycle analysis, and alterations in signaling pathway that play a role in breast cancer progression such as β -catenin, STAT3, cyclin D1, Bax, c-PARP, wild and Mutant p53. In addition the effect of combined treatments were examined on gene expression levels of Cytochromes; CYP1A1, CYP1B1, Aurora kinases; Aurora-A and Aurora-B were determined by RT-PCR.Our data showed that combined treatments of 50 nmol Letrozole or 250 nmol Olaparib with 5 mmol, 2.5mmol Aspirin for 24 and 48 h, respectively, promoted apoptosis induction through enhanced histone release and caspase-3 activation compared to control and cells treated with each drug alone. Furthermore, apoptotic induction was associated with upregulation of Bax and downregulation of Bcl-2, cyclin D1, β-catenin, and STAT3 signaling pathways in both tested cell lines compared to control, suggesting that Aspirin may enhance the sensitivity of tested cells to Letrozole or Olaparib in both (ER) positive and triple negative breast cancer cell lines. In addition, cell cycle analysis showed a cell arrest at G0/G1 phase in both cell lines. Interestingly, in T-47D cells, combined treatment of Letrozole with Aspirin significantly upregulated wild p53 at protein level and downregulated CYP1A1, CYP1B1, Aurora-A, and Aurora-B expression at gene level compared to control, suggesting that combined treatment may inhibit breast cancer cell proliferation via down-regulation of Aurora-A and Aurora-B. In MDA-MB-231 cells, combined treatment of Olaparib with Aspirin showed a significant downregulation of Mutant p53 at protein level and CYP1A1, CYP1B1, Aurora-B and upregulation of Aurora-A at gene level compared to control, suggesting that there is a crosstalk between Olaparib/Aspirin and P53 In conclusion, combined treatment of Letrozole or Olaparib with Aspirin might be a promising approach to inhibit both ER (+) and triple negative breast cancer cell lines survival and proliferation. Citation Format: Marwa Elsayed ElKamel, Salah Sheweita, Ahmed Sultan. Combined treatment of letrozole or olaparib with aspirin inhibits cell proliferation and induces apoptosis through upregulation of wild p53 and modulation of aurora kinases in human breast cancer cell lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 115.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 115
Open AccessAbstract 115: Combined treatment of letrozole or olaparib with aspirin inhibits cell proliferation and induces apoptosis through upregulation of wild p53 and modulation of aurora kinases in human breast cancer cell lines
Although, there are several breakthroughs in the treatment of breast cancer on the past few decades, high incidence of relapse and progression after conventional therapies is deeply concerning, indicating a great need for developing new therapeutics for breast cancer. In the present study, the anti-cancer effects of combinational therapy of Letrozole (Aromatase inhibitor) or Olaparib (PARP inhibitor) with Aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), were examined on well differentiated ER-positive and poorly differentiated triple negative breast cancer cell lines, T-47D and MDA-MB-231, respectively. In addition, the effect of combined treatment was also examined by detecting cell survival, cell cycle analysis, and alterations in signaling pathway that play a role in breast cancer progression such as β -catenin, STAT3, cyclin D1, Bax, c-PARP, wild and Mutant p53. In addition the effect of combined treatments were examined on gene expression levels of Cytochromes; CYP1A1, CYP1B1, Aurora kinases; Aurora-A and Aurora-B were determined by RT-PCR.Our data showed that combined treatments of 50 nmol Letrozole or 250 nmol Olaparib with 5 mmol, 2.5mmol Aspirin for 24 and 48 h, respectively, promoted apoptosis induction through enhanced histone release and caspase-3 activation compared to control and cells treated with each drug alone. Furthermore, apoptotic induction was associated with upregulation of Bax and downregulation of Bcl-2, cyclin D1, β-catenin, and STAT3 signaling pathways in both tested cell lines compared to control, suggesting that Aspirin may enhance the sensitivity of tested cells to Letrozole or Olaparib in both (ER) positive and triple negative breast cancer cell lines. In addition, cell cycle analysis showed a cell arrest at G0/G1 phase in both cell lines. Interestingly, in T-47D cells, combined treatment of Letrozole with Aspirin significantly upregulated wild p53 at protein level and downregulated CYP1A1, CYP1B1, Aurora-A, and Aurora-B expression at gene level compared to control, suggesting that combined treatment may inhibit breast cancer cell proliferation via down-regulation of Aurora-A and Aurora-B. In MDA-MB-231 cells, combined treatment of Olaparib with Aspirin showed a significant downregulation of Mutant p53 at protein level and CYP1A1, CYP1B1, Aurora-B and upregulation of Aurora-A at gene level compared to control, suggesting that there is a crosstalk between Olaparib/Aspirin and P53 In conclusion, combined treatment of Letrozole or Olaparib with Aspirin might be a promising approach to inhibit both ER (+) and triple negative breast cancer cell lines survival and proliferation. Citation Format: Marwa Elsayed ElKamel, Salah Sheweita, Ahmed Sultan. Combined treatment of letrozole or olaparib with aspirin inhibits cell proliferation and induces apoptosis through upregulation of wild p53 and modulation of aurora kinases in human breast cancer cell lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 115.
- 1 March 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (2) , 636-644
Predictive Factors of De Novo Malignancies After Living-Donor Liver Transplantation: A Single-Center Experience
- 1 March 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (2) , 636-644
Predictive Factors of De Novo Malignancies After Living-Donor Liver Transplantation: A Single-Center Experience
- Open Access
- 9 February 2021
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 11 (1) , 1-5
Egyptian protocol for living donor liver transplantation (LDLT) during SARS-CoV-2 pandemic
Background: The current SARS-CoV-2 pandemic may negatively impact the care of liver transplant candidates and recipients. Main body of the Accordingly, each country must have its national guidelines based on the current situation and according to available tools. Liver Transplantation Scientific Committee of Waiting List Project in Egypt was established in 13 April 2020. One of the major objectives of this Scientific Committee is the preparation of national protocol for Transplant Centers in Egypt to deal with living donor liver transplantation (LDLT) during SARS-CoV-2 pandemic. Conclusions: The protocol highlights basic hospital requirements for LDLT during SARS-CoV-2 pandemic, the patient selection from the waiting list, management of patients on the waiting list, and post-transplant management.
- 9 February 2021
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 11 (1) , 1-5
Open AccessEgyptian protocol for living donor liver transplantation (LDLT) during SARS-CoV-2 pandemic
Background: The current SARS-CoV-2 pandemic may negatively impact the care of liver transplant candidates and recipients. Main body of the Accordingly, each country must have its national guidelines based on the current situation and according to available tools. Liver Transplantation Scientific Committee of Waiting List Project in Egypt was established in 13 April 2020. One of the major objectives of this Scientific Committee is the preparation of national protocol for Transplant Centers in Egypt to deal with living donor liver transplantation (LDLT) during SARS-CoV-2 pandemic. Conclusions: The protocol highlights basic hospital requirements for LDLT during SARS-CoV-2 pandemic, the patient selection from the waiting list, management of patients on the waiting list, and post-transplant management.
- 26 January 2019
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 81 (6) , 557-563
Risk Factors and Predictors of Poor Outcome Following Hepaticojejunostomy for Postcholecystecomy Bile Duct Injury
- 26 January 2019
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 81 (6) , 557-563
Risk Factors and Predictors of Poor Outcome Following Hepaticojejunostomy for Postcholecystecomy Bile Duct Injury
- Open Access
- 1 November 2017
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 22 (11) , 1413
The Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
- 1 November 2017
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 22 (11) , 1413
Open AccessThe Use of Hyperbaric Oxygen for the Prevention and Management of Osteoradionecrosis of the Jaw: A Dana-Farber/Brigham and Women's Cancer Center Multidisciplinary Guideline
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
- Open Access
- 1 July 2017
- Published by Taylor & Francis in Egyptian Journal of Anaesthesia
- Vol. 33 (3) , 233-237
Automated control of end-tidal sevoflurane in living donor hepatectomy, a prospective, randomized, controlled study
Background: Reduction of anesthesia cost has become a necessity, especially in developing countries. Recently, automated control of end-tidal sevoflurane concentration (EtSev) has been proposed as a new technique with both cost-effectiveness and safety profiles. In this study, sevoflurane consumption (primary outcome variable) was evaluated during living donor hepatectomy using automated control of EtSev (EtC) at fresh gas flow (FGF) of 0.5 and 2 L/min compared to manual control (MC) technique at FGF of 2 L/min. Materials and methods: Prospective, randomized, controlled trial including 60 Potential donors scheduled for living donor right hepatectomy. patients were randomized into 3 equal groups (according to target control of sevoflurane), MC group, EtC-2L group, and EtC-0.5L group. In MC group: FGF was set to 2 L/min, inspired concentration of Sevoflurane (FiSev) was set to 1.5–2% in 0.4 fractional inspired oxygen concentration (FiO2), while in EtC-2L group: FGF was set to 2 L/min, EtSev was set to 1–1.5% with end tidal oxygen concentration (EtO2) target of 0.35. In EtC-0.5L group, FGF was set to minimal flow and EtSev target to 1–1.5% and EtO2 target of 0.35. Anesthetic gases consumption (sevoflurane ml, Oxygen L, and air consumption L) per anesthesia hour were recorded at the end of surgery. Other recorded data included intraoperative hemodynamics, the number of user adjustments, and extubation time. Results: Significant reduction in sevoflurane consumption when EtC-0.5L is used (4.2 ± 1.3 ml/h, 12.6 ± 2.6 ml/h, and 15 ± 2.9 ml/h respectively, p. 0.001). Also, a significant decrease in overall numbers of user adjustments between the three groups (8 times for EtC-0.5L group, 7 times in EtC-2L group, 22 times for MC group, p. 0.008) was observed. Conclusion: automated control of EtSev during anesthesia of living donor hepatectomy significantly lowers sevoflurane consumption and decreases required user interventions without deleterious effect on patient safety
- 1 July 2017
- Published by Taylor & Francis in Egyptian Journal of Anaesthesia
- Vol. 33 (3) , 233-237
Open AccessAutomated control of end-tidal sevoflurane in living donor hepatectomy, a prospective, randomized, controlled study
Background: Reduction of anesthesia cost has become a necessity, especially in developing countries. Recently, automated control of end-tidal sevoflurane concentration (EtSev) has been proposed as a new technique with both cost-effectiveness and safety profiles. In this study, sevoflurane consumption (primary outcome variable) was evaluated during living donor hepatectomy using automated control of EtSev (EtC) at fresh gas flow (FGF) of 0.5 and 2 L/min compared to manual control (MC) technique at FGF of 2 L/min. Materials and methods: Prospective, randomized, controlled trial including 60 Potential donors scheduled for living donor right hepatectomy. patients were randomized into 3 equal groups (according to target control of sevoflurane), MC group, EtC-2L group, and EtC-0.5L group. In MC group: FGF was set to 2 L/min, inspired concentration of Sevoflurane (FiSev) was set to 1.5–2% in 0.4 fractional inspired oxygen concentration (FiO2), while in EtC-2L group: FGF was set to 2 L/min, EtSev was set to 1–1.5% with end tidal oxygen concentration (EtO2) target of 0.35. In EtC-0.5L group, FGF was set to minimal flow and EtSev target to 1–1.5% and EtO2 target of 0.35. Anesthetic gases consumption (sevoflurane ml, Oxygen L, and air consumption L) per anesthesia hour were recorded at the end of surgery. Other recorded data included intraoperative hemodynamics, the number of user adjustments, and extubation time. Results: Significant reduction in sevoflurane consumption when EtC-0.5L is used (4.2 ± 1.3 ml/h, 12.6 ± 2.6 ml/h, and 15 ± 2.9 ml/h respectively, p. 0.001). Also, a significant decrease in overall numbers of user adjustments between the three groups (8 times for EtC-0.5L group, 7 times in EtC-2L group, 22 times for MC group, p. 0.008) was observed. Conclusion: automated control of EtSev during anesthesia of living donor hepatectomy significantly lowers sevoflurane consumption and decreases required user interventions without deleterious effect on patient safety
- 1 June 2015
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 18, 205-210
Long-term follow-up of 120 patients after hepaticojejunostomy for treatment of post-cholecystectomy bile duct injuries: A retrospective cohort study
Long-term follow-up is essential for assessment of success of the surgical repair of post-cholecystectomy bile duct injuries (BDI). Factors affecting the long-term outcome and satisfactory length of follow-up have been little reported in the literature. The aim of this study is long-term evaluation of hepaticojejunostomy regarding clinical, radiological, laboratory and quality of life assessment. Between January 1992 to December 2007, 120 patients with postcholecystectomy bile duct injury surgically treated by hepaticojejunostomy Roux-en-Y were followed up for 20 years in Mansoura Gastro-enterology Center. Long-term outcomes and quality of life (QOL) were evaluated for all patients. Univariate and multivariate analyses were done for detection of factors affecting long-term outcome. The median follow up period was 149 months, range (70-246 months). Successful long-term outcome was detected in 106 (88.3%) patients. Long-term complications were detected in 35 (29%) patients. Fourteen (11.6%) patients developed anastomotic stricture within different follow up intervals up to 17 years, of which. Seventeen (14.2%) patients developed recurrent episodes of cholangitis at median interval 48 months, range (2-156 months). Post-ERCP pancreatitis, number of anastomosis, operative time, post-operative early complications, and post-operative bile leak were predictors for poor outcome. Physical component was much more affected than mental component in QOL. Management of BDI in specialized centers is highly recommended. Longer time for follow-up of the patients of surgical repair of bile duct injury up to 20 years should be adopted to ensure successful outcome. Quality of life assessment is essential component of long-term follow-up.
- 1 June 2015
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 18, 205-210
Long-term follow-up of 120 patients after hepaticojejunostomy for treatment of post-cholecystectomy bile duct injuries: A retrospective cohort study
Long-term follow-up is essential for assessment of success of the surgical repair of post-cholecystectomy bile duct injuries (BDI). Factors affecting the long-term outcome and satisfactory length of follow-up have been little reported in the literature. The aim of this study is long-term evaluation of hepaticojejunostomy regarding clinical, radiological, laboratory and quality of life assessment. Between January 1992 to December 2007, 120 patients with postcholecystectomy bile duct injury surgically treated by hepaticojejunostomy Roux-en-Y were followed up for 20 years in Mansoura Gastro-enterology Center. Long-term outcomes and quality of life (QOL) were evaluated for all patients. Univariate and multivariate analyses were done for detection of factors affecting long-term outcome. The median follow up period was 149 months, range (70-246 months). Successful long-term outcome was detected in 106 (88.3%) patients. Long-term complications were detected in 35 (29%) patients. Fourteen (11.6%) patients developed anastomotic stricture within different follow up intervals up to 17 years, of which. Seventeen (14.2%) patients developed recurrent episodes of cholangitis at median interval 48 months, range (2-156 months). Post-ERCP pancreatitis, number of anastomosis, operative time, post-operative early complications, and post-operative bile leak were predictors for poor outcome. Physical component was much more affected than mental component in QOL. Management of BDI in specialized centers is highly recommended. Longer time for follow-up of the patients of surgical repair of bile duct injury up to 20 years should be adopted to ensure successful outcome. Quality of life assessment is essential component of long-term follow-up.